Adverse Effects

Brain Cancer

HER2-Positive Breast Cancer

Triple-Negative Breast Cancer

Breast Cancer

Colorectal Cancer

Esophageal Cancer

Gastric Cancer

Liver Cancer

Pancreatic Cancer

Gastrointestinal Cancer

Bladder Cancer

Kidney Cancer

Prostate Cancer

Genitourinary Cancers

Cervical Cancer

Endometrial Cancer

Ovarian Cancer

Gynecologic Cancers

Head & Neck Cancer

Multiple Myeloma

Myelodysplastic Syndromes

Myeloproliferative Neoplasms

Hematologic Oncology

Vaccines

Infection

Leukemia

Non-Small Cell Lung Cancer (NSCLC)

Small Cell Lung Cancer (SCLC)

Lung Cancer

Lymphoma

Neuroendocrine Tumors

Oncology

Pediatric Cancers

Radiation Oncology

Sarcoma

Screening

Skin Cancer & Melanoma

Surgery

Thyroid Cancer

News

Global Bulletin

All News

FDA Approval Alert

Women in Oncology

Media

Expert Interviews

Around the Practice

Between the Lines

Face Off

From All Angles

Meeting of the Minds

OncView

Podcasts

Training Academy

Treatment Algorithms with the Oncology Brothers

Conferences

Publications

All Journals

Editorial Board

For Authors

Year in Review

Events

Frontline Forum

Satellite Sessions

CME/CE

Resources

Awareness Month

Interactive Tools

Nurse Practitioners/Physician's Assistants

Partners

Career Center

Subscribe

CancerNetwork is home to the journal Oncology & provides insights on the screening, early detection, diagnosis, treatment and prevention of cancers.

About

Advertise

CureToday.com

OncLive.com

OncNursingNews.com

TargetedOnc.com

Editorial

Contact

Terms and Conditions

Privacy

Do Not Sell My Personal Information

CancerNetwork - Oncology News and Clinical Expertise

Facebook

LinkedIn

Spotlight

Clinical

Genitourinary Cancer

Gynecologic Cancer

Hematology

Skin Cancer

1rem

View

FACE-OFF: Team Blue vs Team Purple

Video Series

MEDALIST and IMerge Trial Presentation and Discussion

Videos

Amer Zeidan, MBBS; Catherine Lai, MD; Bart Scott, MD; Andrew Brunner, MD; Jonathan Abbas, MD; Akriti Jain, MD; Mohamed Hegazi, MD; Somedeb Ball, MBBS; and Salman Fazal, MD, examine critical clinical decisions in myelodysplastic syndrome management, including optimal sequencing of erythropoiesis-stimulating agents vs luspatercept, dosing strategies, and efficacy data from pivotal trials such as MEDALIST, IMerge, and ELEMENT-MDS, which demonstrate improvements in transfusion burden and hemoglobin levels.

Panelists discuss how long-term analysis of the ELEMENTS trial reveals significant improvements in red blood cell (RBC) transfusion burden and hemoglobin levels among study participants.

COMMANDS: Long-Term Analysis, Changes in RBC Transfusion Burden, Hemoglobin Levels and ELEMENTS Trial

Panelists discuss how the MEDALIST and IMerge trials provide crucial insights into novel therapeutic approaches for treating myelodysplastic syndromes.

Panelists discuss how clinicians should weigh the decision between initiating treatment with erythropoiesis-stimulating agents (ESAs) vs luspatercept in patients with myelodysplastic syndromes.

Debate: Do We Treat First With ESAs or With Luspatercept? 

Panelists discuss how to optimize luspatercept dosing strategies by evaluating the benefits and risks of starting at maximum dose with downward titration vs initiating at lower doses with upward adjustments.

Do We Start Luspatercept at the Highest Dose and Titrate Down or Start Low and Titrate Up?

Panelists discuss how to approach patients who show inadequate response to initial erythropoiesis-stimulating agent (ESA) therapy, including assessment strategies and potential next steps in treatment modification.

Clinical Scenario: Patient Receiving First-Line ESA Without a Marked Response: What Do You Do Next?

Panelists discuss how to develop treatment strategies for patients with ring sideroblasts and genetic abnormalities, focusing on the role of specialized therapies and the importance of molecular testing in guiding clinical decisions.

Clinical Scenario: How Do We Treat Patients With Ring Sideroblast/Genetic Abnormalities?

CancerNetwork® Face-Off

is a live event hosted by CancerNetwork® in which renowned cancer institutions go head-to-head in a friendly debate on the latest data in a specific therapeutic area. The Face-Off program provides the ideal platform for a meaningful dialogue and data review among fellows and attending junior oncologists, as well as other key stakeholders.

MEDALIST and IMerge Trial Presentation and Discussion

EP: 1.COMMANDS: Long-Term Analysis, Changes in RBC Transfusion Burden, Hemoglobin Levels and ELEMENTS Trial

EP: 2.MEDALIST and IMerge Trial Presentation and Discussion

EP: 3.Debate: Do We Treat First With ESAs or With Luspatercept?

EP: 4.Do We Start Luspatercept at the Highest Dose and Titrate Down or Start Low and Titrate Up?

EP: 5.Clinical Scenario: Patient Receiving First-Line ESA Without a Marked Response: What Do You Do Next?

EP: 6.Clinical Scenario: How Do We Treat Patients With Ring Sideroblast/Genetic Abnormalities?

Newsletter